Health‐related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study

Summary The PETIT (Eltrombopag in Pe diatric Patients with T hrombocytopenia from Chronic IT P) trial showed that in children aged 1–17 years with chronic or persistent immune thrombocytopenia (ITP), eltrombopag improved platelet counts, decreased clinically significant bleeding and reduced rescue medication need. We report the health‐related quality of life (HRQoL) results from the PETIT study using the Kids’ ITP Tools (KIT). A limitation was that PETIT was not powered for the HRQoL analysis. Eltrombopag did not impact children's HRQoL assessed by the KIT. Although median KIT scores in children treated with eltrombopag with platelet responses were numerically higher compared with non‐responders in some age groups, the interquartile ranges overlapped.